Product Description
Rad-67's ability to provide portable spot-check monitoring measurements of both oxygen saturation and noninvasive hemoglobin makes it a single-device solution in multiple clinical and non-clinical settings, such as emergency rooms, pre-/post-surgery settings, and physicians' offices. (Sourced from: https://www.masimo.com/products/monitors/spot-check/rad67/)
Mechanisms of Action: Device
Novel Mechanism: No
Modality: Device
Route of Administration: N/A
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Masimo
Company Location: IRVINE CA 92618
Company CEO: Joe Kiani
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| 2024P000128 | N/A |
Recruiting |
Pregnancy Outcomes|Anemia |
2026-07-01 |
|
| MD21-002 | N/A |
Unknown status |
Anemia |
2022-12-02 |
|
| ACTRN12619000247178 | N/A |
Completed |
Other |
2021-07-29 |
|
| REVAMP Observe | N/A |
Active, not recruiting |
Pregnancy Outcomes|Anemia |
2021-04-27 |